We tested for pharmacological interaction among all pairs of R-CHOP constituents across a full dose range in three DLBCL cell lines and assessed interaction using both the Bliss independence and Loewe additivity criteria. The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.